Short interest in Polynovo (ASX:PNV) shares is easing. What does this mean?

Is the future looking brighter for Polynovo's stock?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The amount of Polynovo Ltd (ASX: PNV) shares in the hands of short sellers has dropped recently.

Over the week ending 13 December, Polynovo shares had a 7.5% short interest.

However, in The Motley Fool Australia's latest weekly short selling breakdown, the company's short interest had dropped to 7.2%.

At the time of writing, the Polynovo share price is $1.51, 0.2% lower than its previous close.

For context, the S&P/ASX 200 Index (ASX: XJO) is up 0.4% this morning.

Let's take a look at what the company's falling short interest might mean for its long-term investors.

most shorted shares webjet

Image source: Getty Images

What does Polynovo's short interest mean for its shares?

The amount of Polynovo's stock held by short sellers has dipped, and it could spell good news for growth investors.

Short sellers aim to profit from a falling share price. Thus, less short selling activity probably means there's greater confidence in the Polynovo share price among some circles.

Perhaps, the rise in apparent confidence is down to its recent performance.

Over the last 30 days, the company's share price has gained 6.6%, boosted by good news released earlier this month.

Polynovo announced it achieved record sales for July and November on 14 December.

It is also recruiting more sales staff in the United States and its search for a new CEO is progressing well.

Additionally, experts are increasingly bullish on the company's stock.

Macquarie recently upgraded its rating for Polynovo's shares to 'outperform', slapping them with a $2.85 price target. That represents an 88% upside on the company's current share price.

As my Foolish colleague, James Mickleboro, recently reported, the broker believes Polynovo's NovoSorb product will be a major catalyst to its growth.

However, the company still sits among the 10 most shorted shares on the ASX. Potentially, due to the stock's performance through 2021.

Since the start of this year, the Polynovo share price has fallen 61%. It's likely many eyes will be on it in the new year in hopes it can correct its tumble.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose

Clarity Pharmaceuticals reports further progress in its SECuRE prostate cancer trial, showing strong PSA responses and new complete responses at…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Why this ASX healthcare stock is at the cusp of a 'Transformational Opportunity' – Expert

This ASX healthcare stock is one to watch.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
ASX Share Market News

Earnings preview: can Cochlear shares rebound?

A decade low share price meets a make-or-break result.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Healthcare Shares

Why I'm watching CSL shares like a hawk in August

A low valuation will look very different depending on what management says about the year ahead.

Read more »

Doctor with stethoscope around neck shrugging.
Earnings Results

CSL reports on 18 August. Can the healthcare giant arrest the slide?

A make-or-break result for Australia's fallen biotech giant.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Regis Healthcare acquires Royal Freemasons' Victorian home care business

Regis Healthcare has announced the acquisition of Royal Freemasons’ home care business, expanding its client base and annualised home care…

Read more »